CSI Market
Sign In | Register

Codiak Biosciences Inc (CDAK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CDAK Annual Cash Flow →
A period-by-period view of cash flow from Codiak Biosciences Inc to Sep 30 2021 helps clarify how Sep 30 2022's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2022)
9 Months 		(Jun 30 2022) (Mar 31 2022) (Dec 31 2021) (Sep 30 2021)
Operating Activities
Income-34.08
Depreciation & amortization3.18
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation7.30
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-2.41
Fair Value Of Redeemable Convertible Preferred Stock Earned In Connection With Sponsored Research Agreement-
Fair Value Of Common Stock Earned In Connection With License Agreement-
Increase Decrease In Operating Lease Right Of Use Assets1.00
Increase Decrease In Contract With Customer Liability-24.97
Non Cash Manufacturing Expense0.46
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.18
Increase (Decrease) in Accrued Liabilities-1.73
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.95
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities2.56
Discontinued operations0.00
Net Cash flow from Operating Activities-45.56
Investing Activities
Capital Expenditures-0.36
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.36
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities20.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-45.92
Total Cash Flow-25.18
4 historic quarters locked

Sign in to unlock the full Codiak Biosciences Inc cash flow history.

Sign In Create Free Account

About Codiak Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-22-021879

Figures are derived from filed reports and may be restated. Historical data is subject to revision.